Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service colorectal resection cases in Mississippi: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 1,080 | 22% |
| 2020 | 3 | 887 | 25% |
| 2021 | 1 | 850 | 32% |
Laparoscopic and open colectomy and proctectomy; stapler, energy, and robotics call point. Professional codes (what the surgeon bills): CPT 44204, 44205, 44207, 44140, 44145, 44160, 45395, 45397; the hospital bills MS-DRG 329, 330, 331.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Mississippi; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 23 | 2,013−6.1%/yr | −6.1%/yr | 5.60.9× | 2% | 2,210 in 2030+1.6%/yr |
| Cholecystectomy & appendectomy |
Colorectal resection in every state, and its device makers · Every procedure market in Mississippi · Every state · Compare with Texas
| 2024 |
| 704 |
| 46% |
| 2025 est. | ≈ 700 | – |
| 2026 est. | ≈ 690 | – |
| 2022 | 1 | 757 | 37% |
| 2023 | 3 | 656 | 42% |
| 2024 | 5 | 704 | 46% |
| 2025 from claims | – | 696 563–817 | 47% |
| 2026 forecast | – | 693 543–870 | 48% |
| 2027 forecast | – | 689 511–910 | 49% |
| 2028 forecast | – | 684 485–945 | 50% |
| 2029 forecast | – | 680 462–975 | 51% |
| 2030 forecast | – | 675 442–1,002 | 52% |
In 2025, 100% inpatient hospital.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| −6.3%/yr |
| 1.7 |
| 0% |
| 3,630 in 20300%/yr |
| North Carolina | 8 | 1,589−6.5%/yr | −6.5%/yr | 1.6 | 0% | 1,360 in 2030−2.6%/yr |
| Virginia | 8 | 1,510−4.9%/yr | −4.9%/yr | 1.5 | 0% | 1,480 in 2030−0.3%/yr |
| Georgia | 9 | 1,488−6.4%/yr | −6.4%/yr | 1.8 | 0% | 1,450 in 2030−0.4%/yr |
| Tennessee | 8 | 1,264−5.6%/yr | −5.6%/yr | 1.8 | 0% | 1,230 in 2030−0.4%/yr |
| Maryland | 9 | 1,152−4.6%/yr | −4.6%/yr | 1.3 | 0% | 1,300 in 2030+2.1%/yr |
| South Carolina | 6 | 1,082−4.9%/yr | −4.9%/yr | 1.6 | 0% | 1,180 in 2030+1.5%/yr |
| Oklahoma | 7 | 875−4%/yr | −4%/yr | 1.8 | 0% | 740 in 2030−2.7%/yr |
| Kentucky | 1 | 825−7.8%/yr | −7.8%/yr | 1.8 | 0% | 700 in 2030−2.7%/yr |
| Alabama | 7 | 775−8.2%/yr | −8.2%/yr | 1.8 | 0% | 760 in 2030−0.3%/yr |
| Louisiana | 3 | 766−7.5%/yr | −7.5%/yr | 1.9 | 0% | 690 in 2030−1.6%/yr |
| Arkansas | 3 | 698−6%/yr | −6%/yr | 1.9 | 0% | 680 in 2030−0.3%/yr |
| West Virginia | 0 | 265−9.2%/yr | −9.2%/yr | 1.3 | 0% | 200 in 2030−4.7%/yr |
| Delaware | 2 | 264−6.1%/yr | −6.1%/yr | 1.6 | 0% | 340 in 2030+4.1%/yr |
| District of Columbia | 1 | 196−6.3%/yr | −6.3%/yr | 3.2 | 0% | 170 in 2030−2.1%/yr |
| 52 |
| 1,864−9.9%/yr |
| −9.9%/yr |
| 5.11.1× |
| 7% |
| 1,780 in 2030−0.8%/yr |
| Antireflux & hiatal hernia surgery | 3 | 297−1.9%/yr | −1.9%/yr | 0.81.0× | 0% | 300 in 2030+0.1%/yr |
| Breast reconstruction | 0 | 123−12%/yr | −12%/yr | 0.30.7× | 58% | 90 in 2030−4.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Intuitive Surgical leads with 78% of company spending on these surgeons in 2025, −12 pts on 2024.
In 2025, 3 companies reported engagement with Mississippi’s surgeons worth $43K in consulting, speaking, meals and travel tied to these products, about $8,557 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.